Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial

IMPORTANCE: The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD). OBJECTIVE: To assess the efficacy and safety of different dupilumab regimens in maintaining response after 16 weeks of initial treatment. DESIGN, SETTING, AND PARTICIPAN...

Descripción completa

Detalles Bibliográficos
Autores principales: Worm, Margitta, Simpson, Eric L., Thaçi, Diamant, Bissonnette, Robert, Lacour, Jean-Philippe, Beissert, Stefan, Kawashima, Makoto, Ferrándiz, Carlos, Smith, Catherine H., Beck, Lisa A., Chan, Kuo-Chen, Chen, Zhen, Akinlade, Bolanle, Hultsch, Thomas, Staudinger, Heribert, Gadkari, Abhijit, Eckert, Laurent, Davis, John D., Rajadhyaksha, Manoj, Graham, Neil M. H., Pirozzi, Gianluca, Stahl, Neil, Yancopoulos, George D., Ardeleanu, Marius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990756/
https://www.ncbi.nlm.nih.gov/pubmed/31876900
http://dx.doi.org/10.1001/jamadermatol.2019.3617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990756/
https://www.ncbi.nlm.nih.gov/pubmed/31876900
http://dx.doi.org/10.1001/jamadermatol.2019.3617

Ejemplares similares